booth No：2411
このページを印刷する
IMBdx, Inc.
| 企業・団体名／英文表記 | IMBdx, Inc. |
|---|---|
| 企業・団体名／フリガナ | IMBdx, Inc. |
| 住所 | 21F BYC Highcity Bldg A, 131 Gasan digital 1-ro, Geumcheon-gu, Seoul, Republic of Korea 08506 |
| 電話番号 | +82-70-5080-2975 |
| ホームページURL | https://www.imbdx.com/eng/ |
| 企業・団体概要 | IMBdx pioneers a revolutionary approach to cancer detection and monitoring by analyzing the genomic profile of tumor DNA from a single blood draw. Through our advanced molecular diagnostic technology and sophisticated bioinformatic pipeline, we provide comprehensive and personalized analysis information crucial for therapy selection and monitoring. Utilizing Artificial Intelligence, we analyze clinical Big Data to predict cancer prognosis and treatment response accurately. Our commitment extends globally, as we empower patients and healthcare professionals worldwide with our unique expertise in liquid biopsy technology. By continually developing and enhancing our technologies, we aim to transform the landscape of cancer detection and treatment, offering a powerful platform for conquering cancer. |
| 企業・団体カテゴリ | 検査キット/パーツ |
| 出展概要 | IMBdx is a liquid biopsy-focused precision oncology company that develops minimally invasive, comprehensive genomic profiling (CGP) assays.
IMBdx Inc.’s AlphaLiquid® platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid®100) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect™), AND multi-cancer early detection (CancerFind™). Our proprietary technology detects and analyzes trace amounts of tumor-derived DNA in body fluids using AI-driven bioinformatic algorithms. IMBdx is the dominant liquid biopsy diagnostics provider in South Korea and a growing global business. We also offer customized solutions for biopharma companies to assist in biomarker validation and companion diagnostics development. |
AlphaLiquid® 100
検査キット/パーツ
CancerFind™
検査キット/パーツ
CancerDetect™
検査キット/パーツ
